WIXOM, Mich., Oct. 28, 2010 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, announced today that it will hold an investor conference call on Thursday, November 4, 2010 at 8:30 a.m. ET to discuss its third quarter 2010 results. Robert Chioini, Chairman and CEO, and Thomas Klema, CFO, will be hosting the call to review Rockwell's results. Rockwell will be releasing the earnings results on the same date.
Date: November 4, 2010 Time: 8:30 AM ETWhen calling in, investors should refer to the Rockwell Medical Investor Conference Call and provide the operator with their name and company affiliation. Investors who prefer to participate via internet may use the following link: http://ir.rockwellmed.com/ Schedule this webcast into MS-Outlook calendar (click open when prompted): http://apps.shareholder.com/PNWOutlook/t.aspx?m=44921&k=4AF62B18
Toll-free: (877) 383 - 7438 International: (678) 894 - 3975About SFP: SFP is a novel, investigational, continuous iron therapy designed to treat iron deficiency anemia in ESRD patients. SFP is a proprietary, water-soluble form of iron that travels directly to the bloodstream and transfers iron at a cellular level, similar to normal physiologic dietary iron intake. SFP is designed as a continuous maintenance treatment delivering small doses of iron during every dialysis session in order to replenish iron lost during the dialysis procedure, thereby maintaining hemoglobin in the target range as per Kidney Disease Quality Outcomes Initiative (KDQOI) recommendations. Clinical trials to date suggest that SFP, delivered during each dialysis treatment via dialysate, maintains optimal iron balance and avoids liver toxicity while decreasing associated drug administration costs. Recent academic studies have shown that more frequent maintenance doses of iron improve the therapeutic response to erythropoiesis-stimulating agents (ESA), thereby decreasing the ESA doses needed to maintain hemoglobin in the target range. Rockwell Medical has licensed exclusive world-wide rights to manufacture and sell SFP and patents have been issued for SFP in multiple countries, including the three largest dialysis markets in the world: the United States, Japan, and the European Union. Based on current market data, the U.S. dialysis market for IV iron is approximately $560 million annually while global market potential is approximately $850 million.